Trending...
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
- "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
- CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
- American Garden Rose Selections™ Announces 2027 Winners
- Crossroads4Hope Launches Blood Cancer Resource Hub
- NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
- Georgia's Magical Nights of Lights Bigger and Brighter for 2026
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
- Men Moving Mountains Expands Full-Service Moving Options in Boone, NC and the High Country
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
- NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
- OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
- Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
- Travel Season Turns to the Smokies as KayeDinero Turns Cherokee Into a Song
- DBF Viewer 2000 v9.32 Adds New Control for Data Export
- Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
- Cabinet Revolution Expands Affordable Cabinet Options for High Country Homes
- Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
- Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
- Shuttle Buddy Announces Amazon Partnership to Launch Workforce Express in North Carolina
- Inlow Upholstery Helps Cleveland County Homeowners Refresh Furniture with Custom Upholstery
- Birthstones Are Having a 2026 Moment. KayeDinero's "Aquamarine" Began With Her Grandmother
- Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
- Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- A Dependable Marks 29 Years of Home Remodeling and General Contracting in the Charlotte Region
- Living Waters Inc to Host Mental Health Summit
- Black Diamond Sport & Entertainment Group Signs Defensive End Camar Kyle for Representation
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- The Marcus Harris Foundation Awarded Grant From Macon County Community Foundation
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP